Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
Background Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial. Objectives To determine whethe...
Gespeichert in:
| Veröffentlicht in: | Helicobacter (Cambridge, Mass.) Mass.), 2014-10, Vol.19 (5), p.372-381 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 5 |
| container_start_page | 372 |
| container_title | Helicobacter (Cambridge, Mass.) |
| container_volume | 19 |
| creator | Wang, Youhua Wang, Ben Lv, Zhi Fa Yang, Yang Wang, Fucai Wang, Hui Chen, Shuping Xie, Yong Zhou, Xiaojiang |
| description | Background
Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial.
Objectives
To determine whether ecabet sodium improves the eradication rate of H. pylori and examine treatment safety by conducting a meta‐analysis based on randomized controlled trials (RCTs).
Methods
Literature searches were conducted in the following databases: PubMed, Embase, the Cochrane Library, the Science Citation Index, the China National Knowledge Infrastructure Database, and the Wanfang Database. A meta‐analysis of all RCTs comparing ecabet sodium supplementation with nonecabet sodium‐containing therapy was performed.
Results
Thirteen RCTs that included a total of 1808 patients were assessed. The meta‐analysis showed that the eradication rate in the ecabet sodium‐containing quadruple therapy group was higher than that in the standard triple therapy group (84.5% vs 74.55%, OR 1.757 (95%CI: 1.307 to 2.362), p |
| doi_str_mv | 10.1111/hel.12136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566849997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1561967137</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4946-aa7c2a451287f9037e3ce6b4ce48d927051513ccf0bce98b94ecb696b5b9df9a3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQhyMEoqVw4AWQJS5wSGvHf2JzW6J0F2kBiS3iaDnOWPWSbBY7ackL9Llxu20PSEj4Mrbmm9_I-rLsNcGnJJ2zS-hOSUGoeJIdE17QnNNSPk13LGnOqFRH2YsYtxhjTpl6nh0VTBZCYnWc3dTOeWvsjMyuRRvjYJzR4FBtTQMj2gytn3pkYmqjRbudrsxuRBeXEMx-Rm4IaAWdt0Nj7AgB7eduCB7VwbQpdPTD7gNaoM0cR-jT06JvcOXh-m7XZxhNvtiZbo4-vsyeOdNFeHVfT7Lv5_VFtcrXX5efqsU6t0wxkRtT2sIwTgpZOoVpCdSCaJgFJltVlJgTTqi1DjcWlGwUA9sIJRreqNYpQ0-yd4fcfRh-TRBH3ftooevMDoYpasKFkEwpVf4PSpQoCb1F3_6FbocppK8lSvCSESELmaj3B8qGIcYATu-D702YNcH61qNOHvWdx8S-uU-cmh7aR_JBXALODsC172D-d5Je1euHyPww4ZON348TJvzUoqQl1z--LPVHvFRVJSpN6B_KzbWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657416828</pqid></control><display><type>article</type><title>Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wang, Youhua ; Wang, Ben ; Lv, Zhi Fa ; Yang, Yang ; Wang, Fucai ; Wang, Hui ; Chen, Shuping ; Xie, Yong ; Zhou, Xiaojiang</creator><creatorcontrib>Wang, Youhua ; Wang, Ben ; Lv, Zhi Fa ; Yang, Yang ; Wang, Fucai ; Wang, Hui ; Chen, Shuping ; Xie, Yong ; Zhou, Xiaojiang</creatorcontrib><description>Background
Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial.
Objectives
To determine whether ecabet sodium improves the eradication rate of H. pylori and examine treatment safety by conducting a meta‐analysis based on randomized controlled trials (RCTs).
Methods
Literature searches were conducted in the following databases: PubMed, Embase, the Cochrane Library, the Science Citation Index, the China National Knowledge Infrastructure Database, and the Wanfang Database. A meta‐analysis of all RCTs comparing ecabet sodium supplementation with nonecabet sodium‐containing therapy was performed.
Results
Thirteen RCTs that included a total of 1808 patients were assessed. The meta‐analysis showed that the eradication rate in the ecabet sodium‐containing quadruple therapy group was higher than that in the standard triple therapy group (84.5% vs 74.55%, OR 1.757 (95%CI: 1.307 to 2.362), p < .001). The analysis also showed that the eradication rate in the ecabet sodium‐containing triple therapy group was significantly higher than that in the PPI plus amoxicillin or clarithromycin therapy group (74.6% vs 43.9%,OR 3.727 (95%CI: 2.320 to 5.988), p < .001)(ITT), (74.6% vs 43.9%,OR 3.863 (95%CI: 2.369 to 6.298), p < .001) (PP). Furthermore, our meta‐analysis suggested that the occurrence of side effects did not significantly differ between patients receiving ecabet sodium‐containing therapy and patients receiving nonecabet sodium‐containing therapy (14.0% vs 13.3%, OR 1.055 (95%CI: 0.632 to 1.759), p = .839).
Conclusion
Supplementation with ecabet sodium during H. pylori eradication therapy improves the eradication rate. The use of ecabet sodium does not increase the side effects based on our meta‐analysis.</description><identifier>ISSN: 1083-4389</identifier><identifier>EISSN: 1523-5378</identifier><identifier>DOI: 10.1111/hel.12136</identifier><identifier>PMID: 24826809</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>adjuvant therapy ; Amoxicillin - therapeutic use ; Anti-Infective Agents - therapeutic use ; Anti-Ulcer Agents - therapeutic use ; Clarithromycin - therapeutic use ; Diterpenes, Abietane - therapeutic use ; Drug Therapy, Combination ; ecabet sodium ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Helicobacter pylori - drug effects ; Humans ; meta-analysis ; side effects</subject><ispartof>Helicobacter (Cambridge, Mass.), 2014-10, Vol.19 (5), p.372-381</ispartof><rights>2014 John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons Ltd.</rights><rights>Copyright © 2014 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4946-aa7c2a451287f9037e3ce6b4ce48d927051513ccf0bce98b94ecb696b5b9df9a3</citedby><cites>FETCH-LOGICAL-c4946-aa7c2a451287f9037e3ce6b4ce48d927051513ccf0bce98b94ecb696b5b9df9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhel.12136$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhel.12136$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24826809$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Youhua</creatorcontrib><creatorcontrib>Wang, Ben</creatorcontrib><creatorcontrib>Lv, Zhi Fa</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Wang, Fucai</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Chen, Shuping</creatorcontrib><creatorcontrib>Xie, Yong</creatorcontrib><creatorcontrib>Zhou, Xiaojiang</creatorcontrib><title>Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</title><title>Helicobacter (Cambridge, Mass.)</title><addtitle>Helicobacter</addtitle><description>Background
Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial.
Objectives
To determine whether ecabet sodium improves the eradication rate of H. pylori and examine treatment safety by conducting a meta‐analysis based on randomized controlled trials (RCTs).
Methods
Literature searches were conducted in the following databases: PubMed, Embase, the Cochrane Library, the Science Citation Index, the China National Knowledge Infrastructure Database, and the Wanfang Database. A meta‐analysis of all RCTs comparing ecabet sodium supplementation with nonecabet sodium‐containing therapy was performed.
Results
Thirteen RCTs that included a total of 1808 patients were assessed. The meta‐analysis showed that the eradication rate in the ecabet sodium‐containing quadruple therapy group was higher than that in the standard triple therapy group (84.5% vs 74.55%, OR 1.757 (95%CI: 1.307 to 2.362), p < .001). The analysis also showed that the eradication rate in the ecabet sodium‐containing triple therapy group was significantly higher than that in the PPI plus amoxicillin or clarithromycin therapy group (74.6% vs 43.9%,OR 3.727 (95%CI: 2.320 to 5.988), p < .001)(ITT), (74.6% vs 43.9%,OR 3.863 (95%CI: 2.369 to 6.298), p < .001) (PP). Furthermore, our meta‐analysis suggested that the occurrence of side effects did not significantly differ between patients receiving ecabet sodium‐containing therapy and patients receiving nonecabet sodium‐containing therapy (14.0% vs 13.3%, OR 1.055 (95%CI: 0.632 to 1.759), p = .839).
Conclusion
Supplementation with ecabet sodium during H. pylori eradication therapy improves the eradication rate. The use of ecabet sodium does not increase the side effects based on our meta‐analysis.</description><subject>adjuvant therapy</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Clarithromycin - therapeutic use</subject><subject>Diterpenes, Abietane - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>ecabet sodium</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - drug effects</subject><subject>Humans</subject><subject>meta-analysis</subject><subject>side effects</subject><issn>1083-4389</issn><issn>1523-5378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQhyMEoqVw4AWQJS5wSGvHf2JzW6J0F2kBiS3iaDnOWPWSbBY7ackL9Llxu20PSEj4Mrbmm9_I-rLsNcGnJJ2zS-hOSUGoeJIdE17QnNNSPk13LGnOqFRH2YsYtxhjTpl6nh0VTBZCYnWc3dTOeWvsjMyuRRvjYJzR4FBtTQMj2gytn3pkYmqjRbudrsxuRBeXEMx-Rm4IaAWdt0Nj7AgB7eduCB7VwbQpdPTD7gNaoM0cR-jT06JvcOXh-m7XZxhNvtiZbo4-vsyeOdNFeHVfT7Lv5_VFtcrXX5efqsU6t0wxkRtT2sIwTgpZOoVpCdSCaJgFJltVlJgTTqi1DjcWlGwUA9sIJRreqNYpQ0-yd4fcfRh-TRBH3ftooevMDoYpasKFkEwpVf4PSpQoCb1F3_6FbocppK8lSvCSESELmaj3B8qGIcYATu-D702YNcH61qNOHvWdx8S-uU-cmh7aR_JBXALODsC172D-d5Je1euHyPww4ZON348TJvzUoqQl1z--LPVHvFRVJSpN6B_KzbWA</recordid><startdate>201410</startdate><enddate>201410</enddate><creator>Wang, Youhua</creator><creator>Wang, Ben</creator><creator>Lv, Zhi Fa</creator><creator>Yang, Yang</creator><creator>Wang, Fucai</creator><creator>Wang, Hui</creator><creator>Chen, Shuping</creator><creator>Xie, Yong</creator><creator>Zhou, Xiaojiang</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201410</creationdate><title>Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</title><author>Wang, Youhua ; Wang, Ben ; Lv, Zhi Fa ; Yang, Yang ; Wang, Fucai ; Wang, Hui ; Chen, Shuping ; Xie, Yong ; Zhou, Xiaojiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4946-aa7c2a451287f9037e3ce6b4ce48d927051513ccf0bce98b94ecb696b5b9df9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>adjuvant therapy</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Clarithromycin - therapeutic use</topic><topic>Diterpenes, Abietane - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>ecabet sodium</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - drug effects</topic><topic>Humans</topic><topic>meta-analysis</topic><topic>side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Youhua</creatorcontrib><creatorcontrib>Wang, Ben</creatorcontrib><creatorcontrib>Lv, Zhi Fa</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Wang, Fucai</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Chen, Shuping</creatorcontrib><creatorcontrib>Xie, Yong</creatorcontrib><creatorcontrib>Zhou, Xiaojiang</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Helicobacter (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Youhua</au><au>Wang, Ben</au><au>Lv, Zhi Fa</au><au>Yang, Yang</au><au>Wang, Fucai</au><au>Wang, Hui</au><au>Chen, Shuping</au><au>Xie, Yong</au><au>Zhou, Xiaojiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</atitle><jtitle>Helicobacter (Cambridge, Mass.)</jtitle><addtitle>Helicobacter</addtitle><date>2014-10</date><risdate>2014</risdate><volume>19</volume><issue>5</issue><spage>372</spage><epage>381</epage><pages>372-381</pages><issn>1083-4389</issn><eissn>1523-5378</eissn><abstract>Background
Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial.
Objectives
To determine whether ecabet sodium improves the eradication rate of H. pylori and examine treatment safety by conducting a meta‐analysis based on randomized controlled trials (RCTs).
Methods
Literature searches were conducted in the following databases: PubMed, Embase, the Cochrane Library, the Science Citation Index, the China National Knowledge Infrastructure Database, and the Wanfang Database. A meta‐analysis of all RCTs comparing ecabet sodium supplementation with nonecabet sodium‐containing therapy was performed.
Results
Thirteen RCTs that included a total of 1808 patients were assessed. The meta‐analysis showed that the eradication rate in the ecabet sodium‐containing quadruple therapy group was higher than that in the standard triple therapy group (84.5% vs 74.55%, OR 1.757 (95%CI: 1.307 to 2.362), p < .001). The analysis also showed that the eradication rate in the ecabet sodium‐containing triple therapy group was significantly higher than that in the PPI plus amoxicillin or clarithromycin therapy group (74.6% vs 43.9%,OR 3.727 (95%CI: 2.320 to 5.988), p < .001)(ITT), (74.6% vs 43.9%,OR 3.863 (95%CI: 2.369 to 6.298), p < .001) (PP). Furthermore, our meta‐analysis suggested that the occurrence of side effects did not significantly differ between patients receiving ecabet sodium‐containing therapy and patients receiving nonecabet sodium‐containing therapy (14.0% vs 13.3%, OR 1.055 (95%CI: 0.632 to 1.759), p = .839).
Conclusion
Supplementation with ecabet sodium during H. pylori eradication therapy improves the eradication rate. The use of ecabet sodium does not increase the side effects based on our meta‐analysis.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24826809</pmid><doi>10.1111/hel.12136</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-4389 |
| ispartof | Helicobacter (Cambridge, Mass.), 2014-10, Vol.19 (5), p.372-381 |
| issn | 1083-4389 1523-5378 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1566849997 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | adjuvant therapy Amoxicillin - therapeutic use Anti-Infective Agents - therapeutic use Anti-Ulcer Agents - therapeutic use Clarithromycin - therapeutic use Diterpenes, Abietane - therapeutic use Drug Therapy, Combination ecabet sodium Helicobacter Infections - drug therapy Helicobacter pylori Helicobacter pylori - drug effects Humans meta-analysis side effects |
| title | Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A37%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Ecabet%20Sodium%20as%20an%20Adjuvant%20Therapy%20for%20Helicobacter%20pylori%20Eradication:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Helicobacter%20(Cambridge,%20Mass.)&rft.au=Wang,%20Youhua&rft.date=2014-10&rft.volume=19&rft.issue=5&rft.spage=372&rft.epage=381&rft.pages=372-381&rft.issn=1083-4389&rft.eissn=1523-5378&rft_id=info:doi/10.1111/hel.12136&rft_dat=%3Cproquest_cross%3E1561967137%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657416828&rft_id=info:pmid/24826809&rfr_iscdi=true |